Skip to main
REPL
REPL logo

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Hold
Strong Buy 25%
Buy 13%
Hold 50%
Sell 13%
Strong Sell 0%

Bulls say

Replimune Group Inc. is positioned favorably within the biotechnology sector due to its innovative RPx platform for developing oncolytic immunotherapies, which harnesses the immune system against solid tumors. The company has a robust pipeline featuring candidates like RP1, RP2, and RP3, indicating a commitment to advancing cutting-edge cancer treatment options. With primary revenue generation in the USA and the potential for significant growth in the oncolytic therapy market, Replimune's strategic focus enhances its appeal as a promising investment in the biotechnology landscape.

Bears say

Replimune Group Inc faces significant risks that contribute to a negative outlook on its stock, notably the potential inability to generate compelling efficacy and safety data for its lead candidate, RP1, in future clinical trials. The company has encountered issues with the FDA's assessment of its IGNYTE trial, which was deemed inadequate in demonstrating substantial evidence of effectiveness, and concerns regarding patient population heterogeneity and trial design may hinder the interpretation of results. Additionally, the threat of medium- to long-term dilution and challenges in obtaining regulatory approval for RP1 may further exacerbate financial instability and investor confidence.

REPL has been analyzed by 8 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 13% recommend Buy, 50% suggest Holding, 13% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Hold based on their latest research and market trends.

According to 8 analysts, REPL has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.